Brocresine in Parkinson's disease. Action of a peripheral and central decarboxylase inhibitor in potentiating levodopa.
Brocresine, an aromatic L-amino acid decarboxylase inhibitor with both a peripheral and central action was shown to potentiate the therapeutic effect of levodopa in Parkinson's disease. The search for useful decarboxylase inhibitors therefore need not be limited to agents that do not pass the blood/brain barrier.
D001812:Blood-Brain Barrier; D001921:Brain / Q000201:enzymology*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D003408:Cresols / Q000627:therapeutic use*; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D004357:Drug Synergism; D005069:Evaluation Studies as Topic; D006801:Humans; D006898:Hydroxylamines / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology
D003408:Cresols; D006898:Hydroxylamines; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases